Key Highlights of the Plasma Protein Therapeutics Market 2025-2034: Growth Dynamics, Trends, and Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What is the Forecasted Expansion Rate of the Plasma Protein Therapeutics Market Over the 2025–2034 Period?
There has been a significant increase in the size of the plasma protein therapeutics market in the previous years. The market size is predicted to elevate from $31.86 billion in 2024 to about $34.55 billion in 2025, marking a compound annual growth rate (CAGR) of 8.5%. This substantial growth during the past period has been influenced by factors such as growing number of rare diseases, an aging global population, an increase in the supply of blood plasma, a surge in hemophilia cases, advancements in diagnosis techniques, and a favorable regulatory framework.
Expectations are high that the plasma protein therapeutics market will see robust growth in the coming years. The market is predicted to reach $46.35 billion by 2029, with a compound annual growth rate (CAGR) of 7.6%. Factors contributing to this anticipated growth in the forecast period include progress in gene therapy, higher healthcare expenditure, extended indications, precision medicine methodologies, and patient access programs. In addition, major trends for the future include embracing telemedicine, innovative technology, advancements in plasma fractionation technology, pioneering next-generation therapies, and adopting recombinant and personalized medicine therapies.
What External and Internal Drivers Are Contributing to the Growth of the plasma protein therapeutics Market’s Growth?
The plasma protein therapeutics market’s future growth is expected to be driven by the increasing emergence of autoimmune disorders. This occurs when the body’s immune system wrongly attacks healthy cells, considering them foreign. To handle these autoimmune diseases, therapeutic plasma exchange is employed, which comes to light when the body generates proteins, known as autoantibodies, that mistakenly attack the body’s own part. For instance, research carried out by the UK’s University of Glasgow in May 2023, involving a whopping 22 million people, disclosed that approximately 10% of the UK population is affected by autoimmune disorders, which is more than previously assumed. Therefore, the escalating prevalence of autoimmune disorders is putting the plasma protein therapeutics market on an upward trajectory.
Get Your Free Sample of the Global Plasma Protein Therapeutics Market Report Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=9213&type=smp
Who Are the Leading Organizations Fueling the Expansion of the Plasma Protein Therapeutics Market?
Major companies operating in the plasma protein therapeutics market include:
• CSL Behring LLC_x000D_
• Grifols SA_x000D_
• China Biologic Products Holdings Inc._x000D_
• Takeda Pharmaceutical Company Limited_x000D_
• Baxter International Inc._x000D_
Which Cutting-Edge Trends Are Expected to Drive the Plasma Protein Therapeutics Market’s Growth?
One key trend making waves in the plasma protein therapeutic market is the drive for product innovations. Companies at the forefront of this sector are placing a significant emphasis on the development of innovative offerings in order to carve out a competitive edge in the market. An illustrative example of this trend was seen in October 2023, when Octapharma AG, a company based in Switzerland, attained approval from European medical authorities for their lyophilized form of the well-known product, octaplasLG. This enhanced version is tailored for pre-hospital transfusions, offering healthcare specialists a practical and efficient solution for the management of patients in dire situations. This development not only stresses Octapharma’s commitment to upgrade patient care, but also reinforces their dedication to fostering innovation in the sphere of blood products.
Get Instant Access to the Global Plasma Protein Therapeutics Market Report with Swift Delivery!
https://www.thebusinessresearchcompany.com/report/plasma-protein-therapeutics-global-market-report
What Are the Core Categories and Segments in the Plasma Protein Therapeutics Market Driving Demand and Growth?
The plasma protein therapeutics market covered in this report is segmented –
1) By Product: Immunoglobulin, Albumin, Coagulation Factor, C1-esterase Inhibitors, Other Products
2) By Route Of Administration: Intravenous, Subcutaneous
3) By Applications: Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, Other Applications
Subsegments:
1) By Immunoglobulin: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)
2) By Albumin: Human Serum Albumin, Recombinant Albumin
3) By Coagulation Factor: Factor VIII, Factor IX, Prothrombin Complex Concentrates
4) By C1-Esterase Inhibitors: Human C1-Esterase Inhibitors, Recombinant C1-Esterase Inhibitors
5) By Other Products: Fibrinogen, Alpha-1 Antitrypsin, Clotting Factor Concentrates
Which Regions Are Most Influential in Expanding the Plasma Protein Therapeutics Market?
North America was the largest region in the plasma protein therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma protein therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Key Parameters Define the Plasma Protein Therapeutics Market’s Scope?
Plasma protein therapeutics refers to therapies derived from plasma and their recombinant analogs. It is used for the treatment of specific medical conditions by replacing missing or deficient proteins found in plasma, allowing recipients to live healthier and more productive lives.
Browse Through More Similar Reports By The Business Research Company:
Blood Cancer Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report
Rituximab Biosimilars Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/rituximab-biosimilar-global-market-report
Isothermal Nucleic Acid Amplification Technology (INAAT) Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
